Roche is rolling out what it describes as a new type of infectious disease diagnostic in Europe, with a single test capable ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could ...

Listening to music while working may one day become a two-way street. | Neurable is putting forward a pair of headphones ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners ...

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop ...

The FDA is elevating three sets of respiratory hardware recalls from Smiths Medical, covering portable ventilators and ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach ...

Context Therapeutics is building up its bank of bispecific antibody candidates. | Context Therapeutics is building up its ...